Fungal infections are a major contributor to infectious disease-related deaths across the
globe. Candida species are among the most common causes of invasive mycotic disease …

Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Background The emergence of antifungal resistance threatens effective treatment of
invasive fungal infection (IFI). Invasive candidiasis is the most common health care …

With increasing number of immunocompromised patients as well as drug resistance in fungi,
the risk of fatal fungal infections in humans increases as well. The action of echinocandins is …

All serious fungal infections need appropriate antifungal therapy for successful patient
outcome. Only a few classes of antifungal drugs are available, so the emergence of …

Antifungal resistance represents a major clinical challenge to clinicians responsible for
treating invasive fungal infections due to the limited arsenal of systemically available …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Candida auris is a multidrug-resistant yeast that causes a wide spectrum of infections,
especially in intensive care settings. We investigated C. auris prevalence among 102 clinical …

The epidemiology of Candida infections has changed in recent years. Although Candida
albicans is still the main cause of invasive candidiasis in most clinical settings, a substantial …